Experienced in Bone Marrow Aspiration

Dr. Alberto Pappo

Hematology | Oncology

St. Jude Children's Research Hospital

262 Danny Thomas Pl,

Memphis, TN

36 Years of Experience

Experienced in Bone Marrow Aspiration

St. Jude Children's Research Hospital

262 Danny Thomas Pl,

Memphis, TN

OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Alberto Pappo is a Hematologist and an Oncologist in Memphis, Tennessee. Dr. Pappo has been practicing medicine for over 36 years and is rated as an Experienced provider by MediFind in Bone Marrow Aspiration. His top areas of expertise are Rhabdomyosarcoma, Adult Soft Tissue Sarcoma, Ewing Sarcoma, Osteosarcoma, and Bone Marrow Aspiration.

His clinical research consists of co-authoring 184 peer reviewed articles and participating in 25 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has participated in 5 clinical trials in the study of Bone Marrow Aspiration.

Specialties

Hematology

Oncology

Licenses

Pediatric Hematology-Oncology in TN

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance

Find your insuranceClose

Accepted insurance plans:

Blue Cross Blue Shield

Cigna

Locations

St. Jude Children's Research Hospital
262 Danny Thomas Pl, Memphis, TN 38105

Call: 901-595-2322

Additional Areas of Focus

Dr. Pappo has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

25 Clinical Trials

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Ensartinib in Patients With Tumors Harboring ALK or ROS1 Genomic Alterations

Enrollment Status: Active_not_recruiting

Publish Date: February 12, 2026

Intervention Type: Procedure, Other, Drug

Study Drug: Ensartinib

Study Phase: Phase 2

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol

Enrollment Status: Active_not_recruiting

Publish Date: February 10, 2026

Intervention Type: Procedure, Drug, Other

Study Drugs: Ensartinib, Erdafitinib, Larotrectinib, Olaparib, Palbociclib, Samotolisib, Selpercatinib, Selumetinib Sulfate, Tazemetostat, Tipifarnib, Ulixertinib, Vemurafenib

Study Phase: Phase 2

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of AG-120 (Ivosidenib) in Patients With Tumors Harboring IDH1 Mutations

Enrollment Status: Active_not_recruiting

Publish Date: January 29, 2026

Intervention Type: Drug

Study Drug: Ivosidenib

Study Phase: Phase 2

A Phase 1/2 Study of the Oral RET Inhibitor LOXO 292 in Pediatric Patients With Advanced RET-Altered Solid or Primary Central Nervous System Tumors

Enrollment Status: Active_not_recruiting

Publish Date: January 06, 2026

Intervention Type: Drug

Study Drug: Selpercatinib

Study Phase: Phase 1/Phase 2

Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients With Non-High-Risk Neuroblastoma

Enrollment Status: Active_not_recruiting

Publish Date: December 22, 2025

Intervention Type: Drug, Procedure, Other

Study Drugs: Carboplatin, Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide

Study Phase: Phase 3

Computerized Cognitive Training for Pediatric Brain Tumor Patients: A Pilot Study

Enrollment Status: Active_not_recruiting

Publish Date: December 05, 2025

Intervention Type: Other, Procedure

Study Phase: Not Applicable

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Tipifarnib in Patients With Tumors Harboring HRAS Genomic Alterations

Enrollment Status: Active_not_recruiting

Publish Date: December 04, 2025

Intervention Type: Drug

Study Drug: Tipifarnib

Study Phase: Phase 2

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-292 in Patients With Tumors Harboring RET Gene Alterations

Enrollment Status: Active_not_recruiting

Publish Date: December 04, 2025

Intervention Type: Procedure, Drug

Study Drug: Selpercatinib

Study Phase: Phase 2

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-101 (Larotrectinib) in Patients With Tumors Harboring Actionable NTRK Fusions

Enrollment Status: Active_not_recruiting

Publish Date: December 03, 2025

Intervention Type: Procedure, Drug

Study Drugs: Larotrectinib, Larotrectinib Sulfate

Study Phase: Phase 2

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of BVD-523FB (Ulixertinib) in Patients With Tumors Harboring Activating MAPK Pathway Mutations

Enrollment Status: Active_not_recruiting

Publish Date: December 03, 2025

Intervention Type: Other, Drug

Study Drug: Ulixertinib

Study Phase: Phase 2

Larotrectinib (LOXO-101, NSC# 788607) for Previously Untreated TRK Fusion Pediatric Solid Tumors and TRK Fusion Relapsed Pediatric Acute Leukemias

Enrollment Status: Active_not_recruiting

Publish Date: December 02, 2025

Intervention Type: Drug

Study Drug: Larotrectinib Sulfate

Study Phase: Phase 2

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Erdafitinib in Patients With Tumors Harboring FGFR1/2/3/4 Alterations

Enrollment Status: Active_not_recruiting

Publish Date: December 02, 2025

Intervention Type: Procedure, Other, Drug

Study Drug: Erdafitinib

Study Phase: Phase 2

An Open-Label Phase 1b Study of the Safety, Tolerability, and Preliminary Antitumor Activity of INCB059872 in Participants With Relapsed or Refractory Ewing Sarcoma

Enrollment Status: Terminated

Publish Date: October 21, 2025

Intervention Type: Drug

Study Phase: Phase 1

A Phase I/II Study of Bosutinib in Pediatric Patients With Newly Diagnosed Chronic Phase or Resistant/Intolerant Ph + Chronic Myeloid Leukemia, Study ITCC-054/COG-AAML1921

Enrollment Status: Active_not_recruiting

Publish Date: September 18, 2025

Intervention Type: Drug

Study Drug: Bosutinib

Study Phase: Phase 1/Phase 2

A Phase 1/2 Study of the Oral TRK Inhibitor Larotrectinib in Pediatric Patients With Advanced Solid or Primary Central Nervous System Tumors

Enrollment Status: Active_not_recruiting

Publish Date: June 22, 2025

Intervention Type: Drug

Study Drug: Larotrectinib (Vitravki, BAY2757556)

Study Phase: Phase 1/Phase 2

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Selumetinib (AZD6244 Hydrogen Sulfate) in Patients With Tumors Harboring Activating MAPK Pathway Mutations

Enrollment Status: Completed

Publish Date: February 05, 2025

Intervention Type: Drug, Other

Study Drugs: Selumetinib, Selumetinib Sulfate

Study Phase: Phase 2

NCI-COG Pediatric MATCH (Molecular Analysis For Therapy Choice)- Phase 2 Subprotocol of LY3023414 in Patients With Solid Tumors

Enrollment Status: Completed

Publish Date: January 27, 2025

Intervention Type: Procedure, Drug

Study Drug: Samotolisib

Study Phase: Phase 2

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Vemurafenib in Patients With Tumors Harboring BRAF V600 Mutations

Enrollment Status: Completed

Publish Date: January 27, 2025

Intervention Type: Other, Drug

Study Drug: Vemurafenib

Study Phase: Phase 2

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Tazemetostat in Patients With Tumors Harboring Alterations in EZH2 or Members of the SWI/SNF Complex

Enrollment Status: Completed

Publish Date: January 27, 2025

Intervention Type: Drug

Study Drug: Tazemetostat

Study Phase: Phase 2

A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, and Cisplatin (TIP) with High-Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide Followed by High-Dose Carboplatin and Etoposide (TI-CE) As First Salvage Treatment in Relapsed or Refractory Germ Cell Tumors

Enrollment Status: Active_not_recruiting

Publish Date: January 13, 2025

Intervention Type: Drug, Procedure

Study Drugs: Paclitaxel, Ifosfamide, Cisplatin, Pegylated G-CSF, G-CSF, Carboplatin, Etoposide Phosphate

Study Phase: Phase 3

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- A Phase 2 Subprotocol of Olaparib in Patients With Tumors Harboring Defects in DNA Damage Repair Genes

Enrollment Status: Completed

Publish Date: December 11, 2024

Intervention Type: Drug

Study Drug: Olaparib

Study Phase: Phase 2

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Palbociclib in Patients With Tumors Harboring Activating Alterations in Cell Cycle Genes

Enrollment Status: Completed

Publish Date: November 01, 2024

Intervention Type: Other, Drug

Study Drug: Palbociclib

Study Phase: Phase 2

A Protocol for Prospectively Collecting Fresh Tumor Tissue in Children and Adolescents With Recurrent or Progressive Solid Malignancies

Enrollment Status: Completed

Publish Date: June 06, 2023

Intervention Type: Other, Procedure

Surgical Ovarian Preservation in Females Undergoing Chemo-Radiotherapy

Enrollment Status: Completed

Publish Date: November 13, 2020

Intervention Type: Procedure

Study Phase: Not Applicable

A Phase I, Open-label, Dose Escalation Study of LDK378 in Pediatric Patients With Malignancies That Have a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK)

Enrollment Status: Completed

Publish Date: June 09, 2020

Intervention Type: Drug

Study Phase: Phase 1

View 24 Less Clinical Trials

184 Total Publications

Pathway for the Development of ATR Inhibitors in Pediatric Malignancies: An ACCELERATE Multistakeholder Analysis.

Journal: JCO precision oncology

Published: January 15, 2026

View All 184 Publications

Similar Doctors

Advanced in Bone Marrow Aspiration

Dr. Muhammad Raza

Hematology Oncology | Hematology | Oncology

Advanced in Bone Marrow Aspiration

Dr. Muhammad Raza

Hematology Oncology | Hematology | Oncology

Laboratory Corporation Of America Holdings

80 Humphreys Center Dr Ste 330,

Memphis, TN

(11.1 miles away)

901-752-6131

Languages Spoken:

English

See accepted insurances

Muhammad Raza is a Hematologist Oncology specialist and a Hematologist in Memphis, Tennessee. Dr. Raza is rated as a Distinguished provider by MediFind in Bone Marrow Aspiration. His top areas of expertise are Multiple Myeloma, Acute Myeloid Leukemia (AML), Acute Myeloblastic Leukemia without Maturation, Bone Marrow Aspiration, and Bone Marrow Transplant.

Advanced in Bone Marrow Aspiration

Dr. Salil Goorha

Hematology Oncology | Hematology | Oncology

Advanced in Bone Marrow Aspiration

Dr. Salil Goorha

Hematology Oncology | Hematology | Oncology

Laboratory Corporation Of America Holdings

80 Humphreys Center Dr Ste 330,

Memphis, TN

(11.1 miles away)

901-752-6131

Languages Spoken:

English

See accepted insurances

Salil Goorha is a Hematologist Oncology specialist and a Hematologist in Memphis, Tennessee. Dr. Goorha is rated as a Distinguished provider by MediFind in Bone Marrow Aspiration. His top areas of expertise are Acute Myeloid Leukemia (AML), Acute Myeloblastic Leukemia without Maturation, Childhood Acute Myeloid Leukemia, Bone Marrow Aspiration, and Bone Marrow Transplant.

Advanced in Bone Marrow Aspiration

Dr. Jason Chandler

Oncology

Advanced in Bone Marrow Aspiration

Dr. Jason Chandler

Oncology

The West Clinic PLLC

7945 Wolf River Blvd,

Germantown, TN

(14.3 miles away)

901-683-0055

Languages Spoken:

English

See accepted insurances

Offers Telehealth

Jason Chandler is an Oncologist in Germantown, Tennessee. Dr. Chandler is rated as a Distinguished provider by MediFind in Bone Marrow Aspiration. His top areas of expertise are Non-Hodgkin Lymphoma, Multiple Myeloma, Lung Cancer, Bone Marrow Aspiration, and Bone Marrow Transplant.

VIEW MORE BONE MARROW ASPIRATION DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Pappo's expertise for a condition

ConditionClose